William Blair Predicts Xencor's Q1 Earnings (NASDAQ:XNCR)

Xencor, Inc. (NASDAQ:XNCR - Free Report) - Analysts at William Blair issued their Q1 2025 earnings per share estimates for shares of Xencor in a research note issued to investors on Monday, April 21st. William Blair analyst M. Phipps anticipates that the biopharmaceutical company will earn ($0.84) per share for the quarter. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Xencor's current full-year earnings is ($3.68) per share. William Blair also issued estimates for Xencor's Q2 2025 earnings at ($0.82) EPS, Q3 2025 earnings at ($0.81) EPS, Q4 2025 earnings at ($0.80) EPS, FY2025 earnings at ($3.27) EPS, FY2026 earnings at ($3.15) EPS, FY2027 earnings at ($3.01) EPS and FY2028 earnings at ($3.05) EPS.

Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The firm had revenue of $52.79 million during the quarter, compared to the consensus estimate of $17.14 million.

A number of other equities analysts also recently issued reports on XNCR. Wells Fargo & Company decreased their price target on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. StockNews.com cut Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Xencor presently has an average rating of "Moderate Buy" and a consensus target price of $33.86.

Xencor Stock Performance

NASDAQ:XNCR opened at $10.65 on Wednesday. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. Xencor has a twelve month low of $7.16 and a twelve month high of $27.24. The stock has a market cap of $750.42 million, a P/E ratio of -3.33 and a beta of 0.90. The firm's fifty day simple moving average is $12.10 and its 200 day simple moving average is $18.60.

Hedge Funds Weigh In On Xencor

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Sanctuary Advisors LLC bought a new position in shares of Xencor during the third quarter valued at $540,000. Barclays PLC lifted its stake in Xencor by 100.7% during the 3rd quarter. Barclays PLC now owns 155,568 shares of the biopharmaceutical company's stock valued at $3,128,000 after acquiring an additional 78,066 shares during the period. Prudential Financial Inc. boosted its holdings in shares of Xencor by 10.7% during the 4th quarter. Prudential Financial Inc. now owns 70,715 shares of the biopharmaceutical company's stock valued at $1,625,000 after acquiring an additional 6,810 shares during the last quarter. Wellington Management Group LLP bought a new stake in shares of Xencor in the fourth quarter worth approximately $632,000. Finally, Geode Capital Management LLC raised its holdings in shares of Xencor by 1.2% during the third quarter. Geode Capital Management LLC now owns 1,455,350 shares of the biopharmaceutical company's stock valued at $29,273,000 after purchasing an additional 17,658 shares during the last quarter.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.